Amarpreet Sawhney Purchases 45,780 Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) Stock

Ocular Therapeutix Inc (NASDAQ:OCUL) Chairman Amarpreet Sawhney bought 45,780 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was acquired at an average price of $2.91 per share, for a total transaction of $133,219.80. Following the acquisition, the chairman now directly owns 898,711 shares in the company, valued at $2,615,249.01. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Amarpreet Sawhney also recently made the following trade(s):

  • On Friday, June 7th, Amarpreet Sawhney acquired 124,468 shares of Ocular Therapeutix stock. The stock was purchased at an average price of $2.92 per share, with a total value of $363,446.56.

Shares of OCUL stock opened at $4.40 on Friday. The business’s 50 day moving average is $3.51. Ocular Therapeutix Inc has a 12-month low of $2.35 and a 12-month high of $7.61. The company has a quick ratio of 9.16, a current ratio of 9.19 and a debt-to-equity ratio of 2.17.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). Ocular Therapeutix had a negative net margin of 2,956.91% and a negative return on equity of 165.85%. The firm had revenue of $0.49 million during the quarter, compared to the consensus estimate of $0.45 million. Equities analysts forecast that Ocular Therapeutix Inc will post -1.45 earnings per share for the current fiscal year.

Several equities research analysts have commented on OCUL shares. Zacks Investment Research lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Tuesday, March 5th. Cantor Fitzgerald reiterated a “buy” rating and issued a $24.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, March 7th. Piper Jaffray Companies set a $14.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a research note on Friday, March 8th. Finally, ValuEngine lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $9.18.

A number of large investors have recently made changes to their positions in OCUL. Teachers Advisors LLC boosted its holdings in Ocular Therapeutix by 24.1% in the 3rd quarter. Teachers Advisors LLC now owns 67,202 shares of the biopharmaceutical company’s stock valued at $462,000 after purchasing an additional 13,061 shares during the period. Vanguard Group Inc. raised its position in Ocular Therapeutix by 6.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,427,533 shares of the biopharmaceutical company’s stock worth $9,821,000 after purchasing an additional 92,335 shares during the period. Vanguard Group Inc raised its position in Ocular Therapeutix by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 1,427,533 shares of the biopharmaceutical company’s stock worth $9,821,000 after purchasing an additional 92,335 shares during the period. Rhumbline Advisers raised its position in Ocular Therapeutix by 50.3% in the 4th quarter. Rhumbline Advisers now owns 43,465 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 14,551 shares during the period. Finally, BlackRock Inc. raised its position in Ocular Therapeutix by 21.8% in the 4th quarter. BlackRock Inc. now owns 2,792,752 shares of the biopharmaceutical company’s stock worth $11,115,000 after purchasing an additional 500,489 shares during the period. 52.33% of the stock is owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

See Also: Holder of Record

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.